Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02892734 | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer | terminated | Phase 2 | 3 | Northwestern UniversityOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT02774681 | Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis | terminated | Phase 2 | 12 | Northwestern UniversityOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT01060345 | A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ | terminated | Phase 2 | 20 | University of ChicagoOTHER | 1 | Apr 9, 2020 | clinicaltrials |
| NCT02003092 | RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 18 | Rexahn Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 6, 2020 | clinicaltrials |
| NCT01545648 | Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer | terminated | Phase 2 | 4 | Hope Rugo, MDOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01891357 | Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer | terminated | Phase 2 | 64 | Women's Cancer Study Group GmbHOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT03318562 | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | terminated | Phase 2 | 3 | Effector TherapeuticsINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT00063934 | Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02299635 | A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations | terminated | Phase 2 | 19 | PfizerINDUSTRY | 6 | Jan 8, 2019 | clinicaltrials |
| NCT01912963 | Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer | terminated | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 5, 2018 | clinicaltrials |
| NCT03358004 | the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment(VICTOR3) | terminated | Phase 2 | 4 | Mario Negri Institute for Pharmacological ResearchOTHER | 3 | Oct 5, 2018 | clinicaltrials |
| NCT01394211 | Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer | terminated | Phase 2 | 2 | University of ArizonaOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT01776008 | Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer | terminated | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | May 8, 2018 | clinicaltrials |
| NCT02379585 | Fasting on Newly Diagnosed Breast Cancer(STEFNE) | terminated | Phase 1 / Phase 2 | 8 | Western Regional Medical CenterOTHER | 1 | Apr 24, 2018 | clinicaltrials |
| NCT02365714 | CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)(CK-SAPBI) | terminated | Phase 1 / Phase 2 | 2 | Georgetown UniversityOTHER | 1 | Apr 13, 2018 | clinicaltrials |
| NCT02345772 | Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy(Neohttp) | terminated | Phase 1 / Phase 2 | 4 | Western Regional Medical CenterOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT01372618 | Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor | terminated | Phase 1 / Phase 2 | 9 | NYU Langone HealthOTHER | 1 | Dec 27, 2017 | clinicaltrials |
| NCT01319539 | MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Aug 30, 2017 | clinicaltrials |
| NCT01754519 | Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery | terminated | Phase 2 | 1 | Roswell Park Cancer InstituteOTHER | 1 | Jul 7, 2017 | clinicaltrials |
| NCT01918306 | GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 11 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 27, 2017 | clinicaltrials |
| NCT01868503 | Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer | terminated | Phase 2 | 7 | Stanford UniversityOTHER | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01151449 | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01729884 | Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer | terminated | Phase 2 | 3 | University of WashingtonOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT02213744 | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients(HERMIONE) | terminated | Phase 2 / Phase 3 | 113 | Merrimack PharmaceuticalsINDUSTRY | 9 | Jan 6, 2017 | clinicaltrials |
| NCT00636441 | Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer | terminated | Phase 2 | 56 | Duke UniversityOTHER | 1 | Dec 11, 2015 | clinicaltrials |
| NCT00148720 | Capecitabine in Women With Operable Breast Cancer | terminated | Phase 2 | 80 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 11, 2015 | clinicaltrials |
| NCT00132002 | Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2015 | clinicaltrials |
| NCT00079326 | Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer | terminated | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00183963 | A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS) | terminated | Phase 2 | 4 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT01329640 | Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01) | terminated | Phase 2 | 9 | Instituto do Cancer do Estado de São PauloOTHER | 1 | May 21, 2014 | clinicaltrials |
| NCT01194427 | A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer | terminated | Phase 2 | 2 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 17, 2013 | clinicaltrials |
| NCT00095888 | 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer | terminated | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00817362 | Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer | terminated | Phase 2 | 29 | Infinity Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 11, 2012 | clinicaltrials |
| NCT00770354 | Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer | terminated | Phase 2 | 110 | Antisoma ResearchINDUSTRY | 1 | Aug 10, 2009 | clinicaltrials |
| NCT00461344 | Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer | terminated | Phase 2 | 20 | SanofiINDUSTRY | 0 | Apr 3, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Jul 16, 2020source: clinicaltrials